ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • June 28, 2017 - June 27, 2019
  • Total Award Amount

  • 6500.00
  • Direct Costs

  • 5000.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman, Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Kutny, Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Whelan, Kimberly   Investigator